Results 251 to 260 of about 393,042 (353)

Efficacy and safety of steroids glucocorticoids compared with supportive therapy for IgA nephropathy: a systematic review and meta-analysis. [PDF]

BMC Nephrol
Qin H, Liu X, Chen J.
europepmc   +1 more source

Machine Learning to Predict Remission Between Six and 24 Months in Rheumatoid Arthritis: Insights from the JAK‐pot Collaboration

Arthritis &Rheumatology, Accepted Article.
Objective To develop, externally validate, and simplify a machine‐learning (ML) model to predict remission between six and 24 months in rheumatoid arthritis (RA) patients initiating TNF inhibitors, JAK inhibitors, IL‐6 inhibitors, abatacept, or rituximab, using data from 11 international registries in the JAK‐pot collaboration.
Zubeyir Salis, Denis Mongin, Denis Choquette, Louis Coupal, Catalin Codreanu, Florenzo Iannone, Roberto Caporali, Tore K Kvien, Sella Provan, Ruth Fritsch‐Stork, Dan Nordström, Nina Trokovic, Karel Pavelka, Jakub Závada, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Irini Flouri, Céline Lamacchia, Michele Iudici, Delphine Courvoisier, Kim Lauper, Axel Finckh   +22 more
wiley   +1 more source

Canadian Society of Nephrology Commentary on the Evolving Kidney Disease Improving Global Outcomes Adult Glomerulonephritis Guidelines. [PDF]

Can J Kidney Health Dis
Jauhal A, Mustafa R, Mathew A, Girard L, Barbour S, Prasad B, Bathini L, Poyah P, Troyanov S, Samanta R, Garland J, Fairhead T, Walsh M, Reich H, Huang SH, Ng J, Marin J, Hladunewich M.   +17 more
europepmc   +1 more source

Behavioral Incentives for Exercise and Intra‐Articular Glucocorticoids for Knee Osteoarthritis: Results From a Factorially Designed Pragmatic Randomized Clinical Trial

Arthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to determine the benefit of a behaviorally designed incentive program and glucocorticoid injections in reducing symptoms and promoting physical activity in patients with knee osteoarthritis (KOA). Methods This was a pragmatic, multisite, factorially designed, blinded, randomized clinical trial.
Joshua F. Baker, Katherine D. Wysham, Mercedes Quinones, Bryant R. England, Kaitian Jin, Marianna Olave, Sarah Wetzel, Rachel L. Gillcrist, Criswell Lavery, Natalie Keller, Bridget Kramer, Bibianna Ateh, Hannah Brubeck, Daniel K. White, Alexis Ogdie, Rui Xiao, Tuhina Neogi, Carla R. Scanzello   +17 more
wiley   +1 more source

Effectiveness of Canakinumab for First-Line Steroid-Free Treatment in Systemic-Onset Juvenile Idiopathic Arthritis and Juvenile Still Disease. [PDF]

ACR Open Rheumatol
Horneff G, Kallinich T, Hufnagel M, Minden K, Weller-Heinemann F, Trauzeddel R, Foell D, Hinze C, Staubi F, Klein A.   +9 more
europepmc   +1 more source

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations

British Journal of Clinical Pharmacology, EarlyView.
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić, Patrick Eustaquio, Elvira Meni Maria Gkrinia, Ivana Stević, Eugen Javor, Yun Wah Lam, Slobodan Janković, Dinko Vitezić   +7 more
wiley   +1 more source

Tocilizumab combined with short-term high-dose glucocorticoids for rapid disease activity control and glucocorticoid reduction in adult-onset Still's disease: a single-center retrospective study. [PDF]

Front Immunol
Zhong SL, Lei YP, Zhou LX, Niu AX, Liu B, He YL, Yang QB.   +6 more
europepmc   +1 more source

Therapeutic drug monitoring of antimicrobials in a paediatric setting: A retrospective single‐centre study

British Journal of Clinical Pharmacology, EarlyView.
Aims Paediatric pharmacokinetics differ significantly from adults due to age‐related physiological changes, necessitating precise dose adjustments. However, data on therapeutic drug monitoring (TDM) implementation in paediatric setting remain limited.
Gianluca Gazzaniga, Stefano Agliardi, Riccardo Giossi, Alice Schianchi, Alessandra Romandini, Thomas Virdis, Silvia Nerini Molteni, Maria Luisa De Angelis, Stefania Paccagnini, Cecilia Gechtman, Alice Proto, Marco Fossati, Silvia Oliveri, Giulia Angela Pattarino, Elena Altieri, Agnese Graziosi, Arianna Pani, Romano Danesi, Stefano Martinelli, Costantino De Giacomo, Francesco Scaglione   +20 more
wiley   +1 more source

Assessing data quality of rheumatoid and psoriatic arthritis patients in the <i>All of Us</i> Research Program. [PDF]

JAMIA Open
Spotnitz M, Giannini J, Clark E, Ostchega Y, Litwin TR, Berman L.   +5 more
europepmc   +1 more source

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source